Overview

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Status:
Active, not recruiting

Trial end date:
2025-11-20

Target enrollment:

Participant gender:

Summary

The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company
Loxo Oncology, Inc.

Collaborators:

Eli Lilly and Company
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company